ACTH: A Literature Course in Six Modules

How this course works

This page is a reading guide to the published literature on adrenocorticotropic hormone (ACTH). It is organised into six modules, each summarising what specific papers described and each ending with an explicit statement of what that evidence cannot support. No protocol, schedule, or personal application is described anywhere on this page. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, diagnosis, or treatment.

• Module 1 — what ACTH is, its class, origin, and the forms studied
• Module 2 — mechanism as described in the literature
• Module 3 — reported outcomes by study (models, endpoints, results)
• Module 4 — ACTH Side Effects: What Studies Report
• Module 5 — pharmacokinetics, where data exist
• Module 6 — regulatory status, stated factually

Module 1: What ACTH Is and How It Has Been Studied

Definition and class

ACTH is a peptide hormone of the melanocortin family. A physiology review described ACTH as a 39-amino-acid peptide released by corticotroph cells of the anterior pituitary that acts on the adrenal cortex to drive glucocorticoid production, operating within the hypothalamic-pituitary-adrenal axis under hypothalamic corticotropin-releasing hormone control and negative feedback from circulating cortisol (PMID 29763207). In classification terms it is an endogenous signalling peptide, not a synthetic research analogue, although synthetic and biologically derived preparations of ACTH-like activity have been used in medicine and in laboratory work.

Origin: the POMC precursor

ACTH is not transcribed directly. It is cleaved from the larger precursor pro-opiomelanocortin (POMC), which also yields melanocyte-stimulating hormones and beta-endorphin. The clinical relevance of that precursor biology was illustrated by a report in which researchers described a novel POMC variant in a patient with obesity and hyperphagia accompanied by increased but functionally defective ACTH, indicating that immunoreactive ACTH measured in blood is not always biologically active ACTH (PMID 35737586). A separate study measured POMC alongside ACTH and cortisol during pediatric cardiac surgery and reported a dissociation between ACTH and cortisol across the perioperative period (PMID 38657653).

Forms and settings in which ACTH has been studied

The literature cited here approaches ACTH from four directions: as an analyte measured for diagnosis, as a hormone whose excess production causes disease, as a signal whose failure causes disease, and as an administered therapy. On the measurement side, researchers evaluated an automated ACTH immunoassay for the diagnosis of pituitary and adrenal-related diseases (PMID 21704612). On the excess side, a case report described an atypical presentation of ectopic ACTH syndrome in an adolescent boy (PMID 32395251). On the failure side, a series described three cases of ACTH resistance syndrome (PMID 30766828). As a therapy, ACTH has been studied in infantile spasms and related epilepsy syndromes (PMID 34862857).

Limits of the evidence in Module 1

The sources summarised above are a physiology review, case reports, small series, and an assay evaluation. They define the molecule and its context but do not constitute a systematic survey of ACTH biology, and none of them compared different ACTH preparations head to head. Terminology in the literature is also inconsistent: "ACTH" may refer to the endogenous 39-amino-acid hormone, to a measured immunoassay value, or to an administered pharmaceutical product, and these are not interchangeable.

Module 2: Mechanism as Described in the Literature

The pituitary-adrenal signalling chain

The physiology review described the canonical sequence: hypothalamic CRH stimulates pituitary corticotrophs, corticotrophs release ACTH, ACTH acts on the adrenal cortex to stimulate glucocorticoid synthesis, and cortisol feeds back to suppress both CRH and ACTH (PMID 29763207). That feedback loop is why a single ACTH value is interpreted in the literature only alongside a simultaneous cortisol value, a pairing that the automated assay evaluation applied when researchers assessed diagnostic performance in pituitary and adrenal disease (PMID 21704612).

Substrate supply: cholesterol delivery to the adrenal cell

Steroid hormones are built from cholesterol, so ACTH signalling is not complete without substrate. A review of adrenal biology described ACTH regulation of scavenger receptor class B type 1 (SR-B1), the receptor that mediates selective uptake of lipoprotein-derived cholesteryl esters for adrenal steroidogenesis (PMID 27242666). In that account, ACTH acts on both the enzymatic machinery and the lipid supply line feeding it.

What failure of the pathway reveals

Mechanistic claims are often strongest where the pathway breaks. Researchers reported three cases of ACTH resistance syndrome in which cortisol production was deficient despite ACTH signalling being present, a pattern the authors used to localise the defect downstream of the pituitary (PMID 30766828). Conversely, the POMC-variant report described elevated immunoreactive ACTH that was biologically defective, separating the measured signal from the delivered signal (PMID 35737586).

Cross-species and pharmacological probes

An animal study reported that isolated fish scales produced cortisol when stimulated with ACTH in vitro, which the authors framed as evidence of ACTH-responsive steroidogenic capacity outside the classical adrenal gland (PMID 36552430). On the secretion side rather than the target side, a case report described the mTOR inhibitor AZD8055 inhibiting ACTH secretion in bilateral ACTH-secreting pheochromocytoma tissue, implicating mTOR signalling in tumoural ACTH output (PMID 30214591).

Limits of the evidence in Module 2

Mechanism here is assembled from a review, a receptor-biology review, human case material, an in vitro fish model, and a single pharmacological case. Fish scale steroidogenesis does not establish the same behaviour in human tissue, and a single-case observation with an mTOR inhibitor is hypothesis-generating rather than confirmatory. None of these papers demonstrated that a mechanism described in tissue translates into a defined clinical outcome.

Module 3: Reported Outcomes by Study

Study-by-study summary

Reading these outcomes carefully

Most of the therapeutic literature cited here concerns pediatric epilepsy syndromes, where ACTH preparations have a long clinical history. The developmental and epileptic encephalopathy study is notable because its declared endpoint was not seizure control but adrenal function during long-term ACTH therapy (PMID 34862857), which makes it a safety-oriented rather than efficacy-oriented dataset. The hemophilia A report is a single case describing ACTH therapy in an unusual comorbidity context (PMID 27896066), and single cases do not establish response rates.

Limits of the evidence in Module 3

No randomised controlled trial appears in this evidence set. Case reports and small series cannot estimate how often an outcome occurs, cannot separate treatment effect from natural history, and are subject to publication bias toward unusual results. The studies also used different populations, ages, and endpoints, so their findings cannot be pooled. Nothing here supports a generalised claim about what ACTH does in healthy adults.

Module 4: ACTH Side Effects: What Studies Report

Adrenal axis effects during therapy

The most systematically examined adverse consideration in this set is the effect of ACTH therapy on the adrenal axis itself. Researchers followed adrenal function during long-term ACTH therapy in patients with developmental and epileptic encephalopathy and reported alterations in adrenal function associated with that therapy (PMID 34862857). The broader physiology review provides the framework for why this is expected: sustained exogenous stimulation and glucocorticoid feedback both act on a closed regulatory loop (PMID 29763207).

Immunological and vaccination-related risk

A dedicated paper examined risks of ACTH therapy for West syndrome in infants who had received BCG vaccination, and researchers framed prior BCG vaccination as a specific risk consideration in that treated population (PMID 33838621). This is a population-specific safety signal tied to infant immunisation schedules, not a general statement about the peptide.

Comorbidity-related risk described in case material

The West syndrome case involving severe hemophilia A was published precisely because coagulation comorbidity complicates the management of ACTH therapy, and the report described how therapy was handled in that setting (PMID 27896066). Separately, the consequences of ACTH excess — as opposed to administered ACTH — were illustrated by the atypical ectopic ACTH syndrome case in an adolescent boy, in which pathological ACTH production drove the clinical picture (PMID 32395251).

Limits of the evidence in Module 4

These are not incidence data. None of the cited papers reported adverse-event rates from a controlled comparison, and case reports describe what happened once rather than how often it happens. The adverse events discussed here arise in pediatric clinical treatment contexts and in disease states of ACTH excess; they cannot be extrapolated to other populations, other preparations, or other exposures. Absence of a reported adverse event in this small set is not evidence of safety.

Module 5: Pharmacokinetics Where Data Exist

What the cited literature supports

The pharmacokinetic record in this verified evidence set is thin, and it is more accurate to describe it as measurement science than as classical PK. The physiology review described ACTH secretion as a regulated, feedback-controlled process within the HPA axis, with circulating concentrations reflecting hypothalamic drive and cortisol feedback rather than a static level (PMID 29763207). Because plasma ACTH is dynamic, analytical method matters: researchers evaluated an automated ACTH assay and assessed its use for diagnosing pituitary and adrenal-related diseases (PMID 21704612).

Why measured ACTH may not equal delivered signal

Two papers directly complicate the assumption that a plasma ACTH concentration predicts downstream effect. The perioperative study reported dissociation between ACTH and cortisol during pediatric cardiac surgery, meaning the two moved independently across the observation period (PMID 38657653). The POMC-variant report described increased but defective ACTH, so immunoassay-detected hormone overstated biological activity (PMID 35737586).

Limits of the evidence in Module 5

No study in this set reported absorption, distribution, half-life, clearance, bioavailability, or exposure-response modelling for any ACTH preparation, and none compared routes of administration. Any numerical pharmacokinetic parameter for ACTH would have to come from sources outside this verified list and is therefore not stated here. Readers should treat this module as a description of measurement behaviour, not as a pharmacokinetic profile.

Module 6: Regulatory Status, Stated Factually

Approved and clinical uses

ACTH occupies an unusual regulatory position because it is simultaneously an endogenous hormone, a clinical laboratory analyte, and the active principle of approved medicinal products in several jurisdictions. Its clinical use in infantile spasms and related pediatric epilepsy syndromes is reflected in the published treatment literature, including the long-term adrenal function study in developmental and epileptic encephalopathy (PMID 34862857) and the West syndrome case reports (PMID 27896066, PMID 33838621). Where such products are marketed, they are prescription medicines administered under physician supervision, and their labelled indications, formulations, and restrictions are set by the relevant national regulator rather than by the research literature.

Diagnostic and laboratory status

Separately from therapeutic products, ACTH functions as a regulated diagnostic analyte. Clinical laboratories measure it using validated immunoassays such as the automated platform researchers evaluated for pituitary and adrenal disease diagnosis (PMID 21704612), and such assays are subject to in vitro diagnostic regulation and laboratory accreditation requirements.

Research-use-only material and compounding

Peptide material labelled "research use only" (RUO) is not an approved drug, is not authorised for human administration, and is not subject to the manufacturing, purity, and labelling controls applied to medicines. In the United States, compounded preparations fall under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act; whether a given substance may be compounded depends on its regulatory classification and on FDA determinations, and compounding does not confer approval. None of the studies cited on this page evaluated RUO material or compounded preparations. This page states regulatory facts for educational context and is not legal advice.

Limits of the evidence in Module 6

Regulatory status is jurisdiction-specific and changes over time; the published studies cited here do not establish, and cannot establish, what is lawful in any particular country or state. Clinical use described in a journal article does not imply marketing authorisation elsewhere.

What the Studies Did Not Test

Across the papers summarised in this course, several questions were never addressed:

1. Healthy-adult administration. No cited study administered ACTH to healthy adults for performance, body composition, recovery, or wellbeing endpoints.
2. Comparative effectiveness. No cited study randomised participants to ACTH versus an alternative therapy with blinded outcome assessment.
3. Long-term safety beyond the reported settings. The adrenal-function work was conducted in a specific pediatric neurological population (PMID 34862857) and does not describe outcomes in other groups.
4. Pharmacokinetic parameters. No cited study reported half-life, clearance, or bioavailability for any preparation.
5. Non-clinical or unsupervised exposure. No cited study evaluated RUO or compounded peptide material, and the in vitro fish scale work (PMID 36552430) and single-case mTOR inhibitor report (PMID 30214591) were mechanistic, not applied.

Readers with questions about ACTH, adrenal testing, or any hormone-related condition should direct them to a licensed physician. This page summarises published research only.

References

• Physiology, Adrenocorticotropic Hormone (ACTH) (StatPearls, 2026)
• Pro-opiomelanocortin and ACTH-cortisol dissociation during pediatric cardiac surgery (Endocrine Connections, 2024)
• AZD8055 inhibits ACTH secretion in a case of bilateral ACTH-secreting pheochromocytoma (Oncology Letters, 2018)
• ACTH Resistance Syndrome: An Experience of Three Cases (Indian Journal of Endocrinology and Metabolism, 2018)
• Obesity and Hyperphagia With Increased Defective ACTH: A Novel POMC Variant (The Journal of Clinical Endocrinology and Metabolism, 2022)
• Adrenal function during long-term ACTH therapy for patients with developmental and epileptic encephalopathy (Epilepsia Open, 2022)
• Fish Scales Produce Cortisol upon Stimulation with ACTH (Animals, 2022)
• An atypical case of ectopic ACTH syndrome in an adolescent boy (Oxford Medical Case Reports, 2020)
• ACTH therapy for West syndrome with severe hemophilia A (Epilepsy & Behavior Case Reports, 2016)
• ACTH Regulation of Adrenal SR-B1 (Frontiers in Endocrinology, 2016)
• Risks of ACTH therapy for West syndrome following BCG vaccination (Epilepsy & Behavior, 2021)
• Use of an automated ACTH assay for the diagnosis of pituitary and adrenal-related diseases (Clinical Biochemistry, 2011)